A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment

K. Reich, M. Augustin*, D. Tha├ži, A. Pinter, A. Leutz, C. Henneges, E. Schneider, A. Schacht, M. Dossenbach, U. Mrowietz

*Corresponding author for this work
5 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment'. Together they form a unique fingerprint.

Medicine & Life Sciences